Previous 10 | Next 10 |
2023-09-06 14:27:04 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The healthcare industry comprises multiple sectors, including biotechnology, pharmaceuticals, and healthcare equipment, each offering a unique and potentially risky opportunity. News regard...
2023-08-29 00:43:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips After I spent many years following Wall Street, there are a few characteristics about the “big money” that stand out for me. One of these traits is that many if not most lar...
2023-08-24 10:23:54 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In the financial markets, not everything always goes up, not everything always goes down. The fluctuations in the share prices of listed companies are constant. For various reasons, there are s...
Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced that the company will host an Investor Day on September 19, 2023, from 9:30 AM ET to 1:00 PM ET. Interested parties can attend the live webcast for the event by registering on the Events and Presentation section of the compan...
2023-08-14 08:25:28 ET More on Revance Therapeutics Revance Therapeutics, Inc. ( RVNC ) Q2 2023 Earnings Call Transcript Revance Therapeutics: PDUFA Catalyst 2023 And Increased Revenues Revance surges 45% as it sees revenue from RHA collection to be between $34M ...
- Provides Revance entry into the $2.5 billion U.S. therapeutic neuromodulator market. 1 - Approval expands the DAXXIFY® label to include efficacy data over the 52-week ASPEN repeat dose clinical study. - DAXXIFY® for cervical dystonia is the first and only peptide...
2023-08-08 22:40:05 ET Revance Therapeutics, Inc. (RVNC) Q2 2023 Earnings Conference Call August 08, 2023, 16:30 ET Company Participants Jessica Serra - Head, IR & ESG Mark Foley - CEO & Director Dustin Sjuts - President Tobin Schilke - CFO & Prin...
2023-08-08 16:40:11 ET Revance Therapeutics press release ( NASDAQ: RVNC ): Q2 GAAP EPS of -$0.80 misses by $0.01 . Revenue of $58.13M (+104.9% Y/Y) misses by $0.81M . Q2 RHA Collection revenue of $31.8 million, a YoY increase of 24.7%. Q2 DAXXIFY revenue o...
- Q2 total revenue of $58.1 million, a YoY increase of 104.9%. - Q2 RHA® Collection revenue of $31.8 million, a YoY increase of 24.7%. - Q2 DAXXIFY® revenue of $22.6 million, a QoQ increase of 47.1%. - Bolstered financial position with $100 million net proceeds from ...
2023-08-07 11:20:35 ET Major earnings expected before the bell on Tuesday include: Duke Energy ( DUK ) Barrick Gold ( GOLD ) Medical Properties Trust ( MPW ) Organon ( OGN ) United Parcel Service ( UPS ) For further details see: Notable ea...
News, Short Squeeze, Breakout and More Instantly...
Revance Therapeutics Inc. Company Name:
RVNC Stock Symbol:
NASDAQ Market:
Revance Therapeutics Inc. Website:
- Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%. - DAXXIFY® net revenue of $22.1 million, after a reduction of $2.0 million related to a consumer coupon program. - Toxin market share increased from 3.0% in Q4’23 to 3...
Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a corresponding confe...